Wealthcare Advisory Partners’s Myriad Genetics MYGN Stock Holding History

Wealthcare Advisory Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,205	Closed	-$37K	–	1362
2021 Q1	$37K	Buy	+1,205	New	+$34.2K	﹤0.01%	985
2020 Q2	–	Sell	-205	Closed	-$3K	–	984
2020 Q1	$3K	Hold	205	–	–	﹤0.01%	1242
2019 Q4	$6K	Hold	205	–	–	﹤0.01%	1070
2019 Q3	$6K	Hold	205	–	–	﹤0.01%	1036
2019 Q2	$6K	Hold	205	–	–	﹤0.01%	1023
2019 Q1	$7K	Hold	205	–	–	﹤0.01%	892
2018 Q4	$6K	Hold	205	–	–	﹤0.01%	896
2018 Q3	$9K	Hold	205	–	–	﹤0.01%	873
2018 Q2	$8K	Buy	205 +100	+95%	+$3.38K	﹤0.01%	897
2018 Q1	$3K	Hold	105	–	–	﹤0.01%	925
2017 Q4	$4K	Hold	105	–	–	﹤0.01%	832
2017 Q3	$4K	Buy	+105	New	+$3K	﹤0.01%	686

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Wealthcare Advisory Partners's MYGN Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 1,205 shares — an estimated $37K sold.

Wealthcare Advisory Partners first reported a position in MYGN in Q3 2017 and held it in 12 quarters. The position peaked at $37K in Q1 2021. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

Wealthcare Advisory Partners reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 1,205 Myriad Genetics shares in Q2 2021, an estimated $37K.
Wealthcare Advisory Partners first reported a position in Myriad Genetics in Q3 2017 and held it in 12 quarters.
Wealthcare Advisory Partners's Myriad Genetics position peaked at $37K in Q1 2021.
201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.